WCN23-0466 PHASE 1 STUDY IN HEALTHY ADULTS OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303, A DUAL BAFF/APRIL ANTAGONIST FOR THE TREATMENT OF AUTOIMMUNE GLOMERULONEPHRITIDES

WCN23-0466 PHASE 1 STUDY IN HEALTHY ADULTS OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303, A DUAL BAFF/APRIL ANTAGONIST FOR THE TREATMENT OF AUTOIMMUNE GLOMERULONEPHRITIDES

Saved in:
Bibliographic Details
Published in:Kidney international reports Vol. 8; no. 3; p. S68
Main Authors: Dillon, S.R., Davies, R., Lickliter, J.D., McLendon, K., Manjarrez, K.L., Smith, A., Lessig, M.C., Blanchfield, L., Sanderson, R.J., Chunyk, A.G., Enstrom, A., Blair, T., Hany Zayed, H.Z., LI, J., Peng, S.L.
Format: Journal Article
Language:English
Published: Elsevier Inc 01-03-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2468-0249
2468-0249
DOI:10.1016/j.ekir.2023.02.151